RNAi therapeutics · Ophthalmic & metabolic diseases · Hypertrophic scars
OliX Pharmaceuticals
A biotech developing RNA-interference drugs, with candidates for hypertrophic scars, eye diseases and metabolic disorders. KOSDAQ large-cap constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
Business categories Pharmaceuticals & Biotechnology · Biopharma & Life Sciences · primary
Other companies in the same category
- Pharmaceuticals & Biotechnology: Alnylam Pharmaceuticals · Regeneron Pharmaceuticals · Moderna · AbbVie · Lilly (Eli)
226950.KQ Updated Jul 11, 2026 2 AI consumers· 1 recurring
Annual return · 2026-10-08'21-40.5%'22-26%'23-29.9%'24+8.9%'25+746%YTD-14.9%
Money in ▸·
OliX Pharmaceuticals
▸ Money out·
Financials & Segments
- Segments · Drug development (RNAi) · Cosmetics (subsidiary)
Revenue from
No refined links yet.
Pays to
No refined links yet.